On Wednesday, Novo Nordisk A/S (NYSE:NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic weight management.NVO is among today's top performers. See the trading setup hereThe new, higher dose of Wegovy (semaglutide 7.2 mg) is currently under review with the European Medicines Agency, in the U.K., and several other countries.In the EU, Novo Nordisk expects a regulatory decision in Q1 2026.Under the C ...